Pancreatic Cancer Research

ResearcherTongji UniversityNo recent work listed

Xiaojun Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0304-0003; OpenAlex author ID A5100362780. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 2 papers

Papers 3

  1. GAS41 mediates proliferation and GEM chemoresistance via H2A.Z.2 and Notch1 in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00675-8↗
  2. Tumor Cell-Specific and Lipase-Responsive Delivery of Hydrogen Sulfide for Sensitizing Chemotherapy of Pancreatic Cancer. Co-author DOI 10.3389/fbioe.2022.934151↗
  3. Stage III should be subclassified into Stage IIIA and IIIB in the American Joint Committee on Cancer (8th Edition) staging system for pancreatic cancer. Last author DOI 10.3748/wjg.v24.i22.2400↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Libing Tian · 1 shared paper, 2022 · strength 0.16
  2. Lichan Chen · 1 shared paper, 2022 · strength 0.16
  3. Shu‐Feng Zhou · 1 shared paper, 2022 · strength 0.16
  4. Rui Liu · 1 shared paper, 2022 · strength 0.15
  5. Xiaoping Zhang · 1 shared paper, 2022 · strength 0.15
  6. Shilong Han · 1 shared paper, 2022 · strength 0.15
  7. Maoquan Li · 1 shared paper, 2022 · strength 0.15
  8. Haifeng Yu · 1 shared paper, 2018 · strength 0.09
  9. Wei Jiang · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.